| Arformoterol | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Arformoterol | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Arformoterol | hsa00190 | Oxidative phosphorylation | 1.94E-02 | 3 | Q16718, P36542, O14521 | NDUFA5, ATP5C1, SDHD | More | |
| Arformoterol | hsa00500 | Starch and sucrose metabolism | 6.17E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
| Arformoterol | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
| Arformoterol | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Arformoterol | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Arformoterol | hsa00730 | Thiamine metabolism | 2.27E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Arformoterol | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Arformoterol | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Arformoterol | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Arformoterol | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Arformoterol | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Arformoterol | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Arformoterol | hsa03013 | RNA transport | 1.39E-04 | 12 | O14980, Q09161, O14893, Q7Z3B4, P35658, P47813, Q14152, O75822, Q14240, Q9BZI7, Q06787, P51114 | XPO1, NCBP1, GEMIN2, NUP54, NUP214, EIF1AX, EIF3A, EIF3J, EIF4A2, UPF3B, FMR1, FXR1 | More | |
| Arformoterol | hsa03022 | Basal transcription factors | 3.50E-02 | 3 | P20226, O00268, Q15544 | TBP, TAF4, TAF11 | More | |
| Arformoterol | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | |
| Arformoterol | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Arformoterol | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | |
| Arformoterol | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Arformoterol | hsa04146 | Peroxisome | 4.83E-02 | 4 | O96011, P56589, Q9UKG9, O75521 | PEX11B, PEX3, CROT, ECI2 | More | |
| Arformoterol | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
| Arformoterol | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
| Arformoterol | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Arformoterol | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Arformoterol | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | |
| Arformoterol | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
| Arformoterol | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Arformoterol | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Arformoterol | hsa04613 | Neutrophil extracellular trap formation | 1.02E-04 | 8 | P11215, Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | ITGAM, HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Arformoterol | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | |
| Arformoterol | hsa04640 | Hematopoietic cell lineage | 4.95E-02 | 3 | P01730, P06127, P09564 | CD4, CD5, CD7 | More | |
| Arformoterol | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Arformoterol | hsa04657 | IL-17 signaling pathway | 8.98E-04 | 7 | O00463, Q16539, P49841, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL2, MMP9, LCN2, TNF | More | |
| Arformoterol | hsa04659 | Th17 cell differentiation | 3.17E-02 | 3 | P25963, P84022, Q13485 | NFKBIA, SMAD3, SMAD4 | More | |
| Arformoterol | hsa04664 | Fc epsilon RI signaling pathway | 3.98E-02 | 3 | P01375, Q16539, Q9UQC2 | TNF, MAPK14, GAB2 | More | |
| Arformoterol | hsa04668 | TNF signaling pathway | 2.12E-03 | 7 | P01375, O00463, Q16539, P18848, P19875, P20749, P14780 | TNF, TRAF5, MAPK14, ATF4, CXCL2, BCL3, MMP9 | More | |
| Arformoterol | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Arformoterol | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Arformoterol | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Arformoterol | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Arformoterol | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Arformoterol | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Arformoterol | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Arformoterol | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
| Arformoterol | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Arformoterol | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Arformoterol | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Arformoterol | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | |
| Arformoterol | hsa05014 | Amyotrophic lateral sclerosis | 2.72E-02 | 10 | P01375, Q16718, O14521, P36542, P09651, Q7Z3B4, P35658, P43243, Q09161, Q16629 | TNF, NDUFA5, SDHD, ATP5C1, HNRNPA1, NUP54, NUP214, MATR3, NCBP1, SFRS7 | More | |
| Arformoterol | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Arformoterol | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Arformoterol | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | |
| Arformoterol | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Arformoterol | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Arformoterol | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
| Arformoterol | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Arformoterol | hsa05150 | Staphylococcus aureus infection | 4.02E-03 | 6 | P21462, O75015, Q14532, P59665, P59666, P12838 | FPR1, FCGR3B, KRT32, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Arformoterol | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Arformoterol | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | |
| Arformoterol | hsa05163 | Human cytomegalovirus infection | 2.80E-02 | 6 | P01375, P49841, P14778, P25025, Q16539, O00463 | TNF, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | |
| Arformoterol | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
| Arformoterol | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
| Arformoterol | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Arformoterol | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Arformoterol | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Arformoterol | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | |
| Arformoterol | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | |
| Arformoterol | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
| Arformoterol | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Arformoterol | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Arformoterol | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Arformoterol | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Arformoterol | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Arformoterol | hsa05418 | Fluid shear stress and atherosclerosis | 1.08E-03 | 7 | Q16539, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | |
| Formoterol | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Formoterol | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Formoterol | hsa00190 | Oxidative phosphorylation | 1.94E-02 | 3 | Q16718, P36542, O14521 | NDUFA5, ATP5C1, SDHD | More | |
| Formoterol | hsa00500 | Starch and sucrose metabolism | 6.17E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
| Formoterol | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
| Formoterol | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Formoterol | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Formoterol | hsa00730 | Thiamine metabolism | 2.27E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Formoterol | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Formoterol | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Formoterol | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Formoterol | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Formoterol | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Formoterol | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Formoterol | hsa03013 | RNA transport | 1.39E-04 | 12 | O14980, Q09161, O14893, Q7Z3B4, P35658, P47813, Q14152, O75822, Q14240, Q9BZI7, Q06787, P51114 | XPO1, NCBP1, GEMIN2, NUP54, NUP214, EIF1AX, EIF3A, EIF3J, EIF4A2, UPF3B, FMR1, FXR1 | More | |
| Formoterol | hsa03022 | Basal transcription factors | 3.50E-02 | 3 | P20226, O00268, Q15544 | TBP, TAF4, TAF11 | More | |
| Formoterol | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | |
| Formoterol | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Formoterol | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | |
| Formoterol | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Formoterol | hsa04146 | Peroxisome | 4.83E-02 | 4 | O96011, P56589, Q9UKG9, O75521 | PEX11B, PEX3, CROT, ECI2 | More | |
| Formoterol | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
| Formoterol | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
| Formoterol | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Formoterol | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Formoterol | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | |
| Formoterol | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
| Formoterol | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Formoterol | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Formoterol | hsa04613 | Neutrophil extracellular trap formation | 1.02E-04 | 8 | P11215, Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | ITGAM, HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Formoterol | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | |
| Formoterol | hsa04640 | Hematopoietic cell lineage | 4.95E-02 | 3 | P01730, P06127, P09564 | CD4, CD5, CD7 | More | |
| Formoterol | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Formoterol | hsa04657 | IL-17 signaling pathway | 8.98E-04 | 7 | O00463, Q16539, P49841, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL2, MMP9, LCN2, TNF | More | |
| Formoterol | hsa04659 | Th17 cell differentiation | 3.17E-02 | 3 | P25963, P84022, Q13485 | NFKBIA, SMAD3, SMAD4 | More | |
| Formoterol | hsa04664 | Fc epsilon RI signaling pathway | 3.98E-02 | 3 | P01375, Q16539, Q9UQC2 | TNF, MAPK14, GAB2 | More | |
| Formoterol | hsa04668 | TNF signaling pathway | 2.12E-03 | 7 | P01375, O00463, Q16539, P18848, P19875, P20749, P14780 | TNF, TRAF5, MAPK14, ATF4, CXCL2, BCL3, MMP9 | More | |
| Formoterol | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Formoterol | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Formoterol | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Formoterol | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Formoterol | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Formoterol | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Formoterol | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Formoterol | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
| Formoterol | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Formoterol | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Formoterol | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Formoterol | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | |
| Formoterol | hsa05014 | Amyotrophic lateral sclerosis | 2.72E-02 | 10 | P01375, Q16718, O14521, P36542, P09651, Q7Z3B4, P35658, P43243, Q09161, Q16629 | TNF, NDUFA5, SDHD, ATP5C1, HNRNPA1, NUP54, NUP214, MATR3, NCBP1, SFRS7 | More | |
| Formoterol | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Formoterol | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Formoterol | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | |
| Formoterol | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Formoterol | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Formoterol | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
| Formoterol | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Formoterol | hsa05150 | Staphylococcus aureus infection | 4.02E-03 | 6 | P21462, O75015, Q14532, P59665, P59666, P12838 | FPR1, FCGR3B, KRT32, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Formoterol | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Formoterol | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | |
| Formoterol | hsa05163 | Human cytomegalovirus infection | 2.80E-02 | 6 | P01375, P49841, P14778, P25025, Q16539, O00463 | TNF, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | |
| Formoterol | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
| Formoterol | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
| Formoterol | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Formoterol | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Formoterol | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Formoterol | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | |
| Formoterol | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | |
| Formoterol | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
| Formoterol | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Formoterol | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Formoterol | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Formoterol | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Formoterol | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Formoterol | hsa05418 | Fluid shear stress and atherosclerosis | 1.08E-03 | 7 | Q16539, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | |
